Hyperbaric oxygen therapy (HBOT) offers significant benefits for managing acute ulcerative colitis (UC) flares, particularly in hospitalized patients at high risk of steroid nonresponse. In trials, 85% of patients avoided second-line therapies, with 70% achieving rectal bleeding resolution by day 5. Long-term data show responders maintained steroid-free remission, with reduced re-hospitalization (10%) and colectomy rates (30%). Meta-analyses highlight HBOT’s role in improving remission rates, reducing inflammatory markers, and boosting anti-inflammatory cytokines. Cost-effectiveness studies project a 60% reduction in complications and a 30% drop in mortality. HBOT is a promising adjunctive therapy.
Have more Questions?